The Multiple Myeloma Research Foundation (MMRF) is a charitable organization dedicated to multiple myeloma, an incurable blood cancer.
The MMRF runs as if it were a for-profit business, expecting high returns from the money the organization raises from donors.
MMRF was founded in 1998 by twin sisters Kathy Giusti and Karen Andrews, following Kathy's diagnosis with multiple myeloma. Giusti, a pharmaceutical company executive and Harvard Business School Alum, wanted to encourage researchers to develop treatments for multiple myeloma by using business models rather than academic models of drug development.
MMRF is a private funder of multiple myeloma research, having raised over $120 million since its inception to contribute funding to more than 120 laboratories worldwide. MMRF funding contributes to diverse research strategies to yield long-, mid-, and short-term results in an effort to deliver better treatments to patients faster: basic science programs to better understand the disease and identify new druggable targets through genomics and proteomics research; validation programs to prioritize new compounds and combinations based on key targets; and clinical trials conducted at a number of myeloma centers.[citation needed]
In 2009, the MMRF funded research into 30 compounds at the pre-clinical stage. By 2013 it had raised more than $250 million and its work has helped gain approval of six new drugs to treat the disease.
This article uses material from the Wikipedia English article Multiple Myeloma Research Foundation, which is released under the Creative Commons Attribution-ShareAlike 3.0 license ("CC BY-SA 3.0"); additional terms may apply (view authors). Content is available under CC BY-SA 4.0 unless otherwise noted. Images, videos and audio are available under their respective licenses.
®Wikipedia is a registered trademark of the Wiki Foundation, Inc. Wiki English (DUHOCTRUNGQUOC.VN) is an independent company and has no affiliation with Wiki Foundation.